Peer-Reviewed Papers
Explore published research on mitochondrial function, cellular energy, (-)-epicatechin,
vascular biology, and related metabolic pathways. Browse by specialization below to quickly
find the papers most relevant to your interests.
Featured Papers
Improving Cardiovascular Risk in Postmenopausal Women with (−)-Epicatechin
Nájera et al., 2024 · Journal of Clinical Medicine
Randomized, double-blind, placebo-controlled proof-of-concept trial evaluating cardiovascular risk–related measures in postmenopausal women using an (−)-epicatechin–enriched cacao supplement.
Antifibrotic Effects of (−)-Epicatechin in High-Glucose–Stimulated Cardiac Fibroblasts
Garate-Carrillo et al., 2021 · Journal of Medicinal Food
Cell-based mechanistic study examining how (−)-epicatechin modulates profibrotic signaling under high-glucose conditions, focusing on GPER and TGF-β1/SMAD pathways.
Effect of (-)-epicatechin on the modulation of progression markers of chronic renal damage in a 5/6 nephrectomy experimental model
Montes-Rivera et al., 2019 · Heliyon
Preclinical study in a progressive chronic kidney disease model assessing the effects of (−)-epicatechin on biomarkers associated with renal injury progression.
Search Papers by Specialization
Epicatechin Activates Nrf2 and Cell Signaling Pathways in HepG2 Cells
Study Title: Epicatechin induces NF-κB, activator protein-1 (AP-1) and nuclear transcription factor erythroid 2p45-related factor-2 (Nrf2) via phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) and extracellular regulated kinase (ERK) signalling in HepG2 cells
Citation: Granado-Serrano et al., 2010 · British Journal of Nutrition
What the Study Found: This laboratory study examined how epicatechin affects stress-response signaling in HepG2 cells, a human liver-derived cell line. The researchers found that epicatechin activated several transcription factors involved in cellular stress and antioxidant-response biology, including NF-κB, AP-1, and Nrf2.
The authors reported that these effects involved PI3K/AKT and ERK signaling pathways. Overall, the study suggests that epicatechin may influence how liver-derived cells respond to oxidative and cellular stress, but these findings were observed in a controlled cell-culture model, not in humans.
What this means in real life: This paper helps explain a possible mechanism behind epicatechin’s biological activity. Rather than acting only as a direct antioxidant, epicatechin may also interact with internal cell-signaling systems that regulate stress response and antioxidant defenses.
Because this was a cell study, it does not prove that epicatechin improves liver function, reduces inflammation, or treats oxidative stress in people. It is best understood as early mechanistic evidence that may help guide future research.
Clinical Relevance: Cell/laboratory study using HepG2 cells; epicatechin, NF-κB, AP-1, Nrf2, PI3K/AKT, ERK signaling, oxidative stress biology, and liver-cell signaling pathways; not an animal study, not a human clinical trial, and not evidence of disease treatment or clinical benefit.
Related Content:
- For a deeper look at epicatechin and mitochondrial support → Mitozz, (-)-Epicatechin and “Mitochondrial Support”
- For a broader explanation of oxidative stress and cellular energy → What Does “Mitochondrial Dysfunction” Actually Feel Like?
- For a practical explanation of mitochondrial renewal and cellular quality control → Mitochondrial Biogenesis and Mitophagy: Build More, Clear Better
Human Pharmacokinetic Study of Purified (−)-Epicatechin
Study Title: Pharmacokinetic, partial pharmacodynamic and initial safety analysis of (−)-epicatechin in healthy volunteers
Citation: Barnett et al., 2015 · Food & Function
What the Study Found: This phase I, open-label human study evaluated purified (−)-epicatechin in healthy volunteers. Participants received single oral doses of 50, 100, or 200 mg, or repeated 50 mg doses once or twice daily for 5 days. The researchers measured absorption, metabolism, early safety, and selected biological markers related to nitric oxide signaling, mitochondrial enzyme activity, and muscle-related pathways.
The authors reported that purified (−)-epicatechin was rapidly absorbed and metabolized, with several metabolites detected in blood. After repeated dosing, the study observed changes in selected biomarkers, including plasma nitrite, platelet mitochondrial enzyme activity, and follistatin measures. No adverse effects attributed to (−)-epicatechin were reported in this small short-term study.
What this means in real life: This study helps distinguish purified (−)-epicatechin from cocoa, dark chocolate, or mixed flavanol products. It shows that purified (−)-epicatechin can be absorbed and measured in humans, and that it may influence biological pathways connected to nitric oxide signaling, vascular biology, mitochondrial enzyme activity, and muscle-related signaling.
These findings are preliminary. The study did not test whether (−)-epicatechin improves fatigue, exercise performance, recovery, cardiovascular outcomes, or any disease condition. Larger and longer clinical trials would be needed to evaluate those questions.
Clinical Relevance: Human phase I pharmacokinetic and partial pharmacodynamic study in healthy volunteers; purified (−)-epicatechin, nitric oxide metabolites, platelet mitochondrial enzyme activity, and follistatin signaling; not a randomized efficacy trial and not evidence that (−)-epicatechin treats, prevents, or cures disease.
Related Content:
- For a deeper look at epicatechin and mitochondrial support → Mitozz, (-)-Epicatechin and “Mitochondrial Support”
- For a practical explanation of endothelial function and vascular health → 8 Simple Everyday Habits That Help Keep Your Arteries Healthy
- For a broader explanation of mitochondrial renewal → Mitochondrial Biogenesis and Mitophagy: Build More, Clear Better
Mitochondrial Transfer and Peripheral Neuropathy
Study Title: Mitochondrial transfer from glia to neurons protects against peripheral neuropathy
Citation: Xu et al., 2026 · Nature
What the Study Found: This study investigated how satellite glial cells in dorsal root ganglia support sensory neurons. The authors found that these glial cells can transfer mitochondria to sensory neurons through tunnelling nanotube-like structures, a process involving the protein MYO10. In mouse and human tissue, the researchers observed structural evidence of these glia-neuron connections. Blocking mitochondrial transfer in mice led to nerve degeneration and neuropathic pain-like behavior, while transfer of human satellite glial cells into mouse dorsal root ganglia provided MYO10-dependent protection against peripheral neuropathy. The findings suggest that mitochondrial sharing between glia and neurons may be an important protective mechanism in peripheral nerve biology.
What this means in real life: Nerve cells have high energy demands, especially sensory neurons with long axons that must maintain function far from the cell body. This study suggests that neurons may not rely only on their own mitochondria. Nearby glial support cells may help maintain neuronal energy capacity by donating mitochondria when needed. That does not mean mitochondrial transfer is a proven treatment for neuropathy in humans, but it expands the way we think about nerve health, showing that cellular energy support can depend on cooperation between different cell types.
Clinical Relevance: Translational study using mouse models, human dorsal root ganglion tissue, diabetic neuropathy context, mitochondrial transfer biology, and neuropathic pain mechanisms; not a human clinical trial.
Related Content:
- For a practical explanation of cellular energy and recovery → What Does “Mitochondrial Dysfunction” Actually Feel Like?
- For a broader look at low energy and cellular capacity → Why Am I Always Tired?
- For the timeline of building mitochondrial capacity → How Long Does It Take to Improve My Mitochondria? A Realistic Timeline for Beginners
Epicatechin and Muscle Wasting After Spinal Cord Injury
Study Title: (-)-Epicatechin reduces muscle waste after complete spinal cord transection in a murine model: role of ubiquitin-proteasome system
Citation: Gonzalez-Ruiz et al., 2020 · Molecular Biology Reports
What the Study Found: This study evaluated (-)-epicatechin in a mouse model of complete spinal cord transection, a severe injury model associated with rapid skeletal muscle wasting. The authors focused on the ubiquitin-proteasome system, a major pathway involved in protein breakdown during muscle atrophy. Compared with untreated injured animals, (-)-epicatechin-treated mice showed reduced loss of muscle mass and changes in molecular markers related to protein degradation. The findings suggest that (-)-epicatechin helped blunt muscle wasting in this model by influencing proteasome-related signaling and muscle catabolism pathways.
What this means in real life: After severe spinal cord injury, muscles can lose size and functional capacity because nerve input, movement, and normal loading are disrupted. This animal study suggests that (-)-epicatechin may affect some of the molecular pathways that drive muscle breakdown after spinal cord injury. It does not show that (-)-epicatechin treats spinal cord injury or prevents muscle loss in humans, but it adds to the scientific literature on epicatechin, neuromuscular biology, and skeletal muscle preservation under extreme disuse conditions.
Clinical Relevance: Animal study, complete spinal cord transection model, skeletal muscle wasting, ubiquitin-proteasome signaling, and neuromuscular injury biology; not direct clinical trial evidence.
Related Content:
- For a practical explanation of cellular energy and recovery → What Does “Mitochondrial Dysfunction” Actually Feel Like?
- For the timeline of building mitochondrial capacity → How Long Does It Take to Improve My Mitochondria? A Realistic Timeline for Beginners
- For a training-focused look at skeletal muscle energy systems → How to Increase Mitochondria for Running
(+)-Epicatechin and Spinal Cord Injury Recovery
Study Title: Positive Effects of (+)-Epicatechin on Traumatic Spinal Cord Injury Recovery
Citation: Gonzalez-Ruiz et al., 2025 · Biomolecules
What the Study Found: This study evaluated (+)-epicatechin in female Long Evans rats with moderate traumatic spinal cord injury. Animals received either vehicle or (+)-epicatechin beginning 24 hours after injury and were followed for 21 days. Compared with vehicle-treated injured rats, the (+)-epicatechin group showed better locomotor recovery on the BBB scale, including a significantly different recovery slope over time. Protein analysis also suggested protection against injury-associated changes in angiopoietin-1, beclin-1, GFAP, myelin basic protein, NeuN, and neurofilament heavy chain. Together, the results suggest that (+)-epicatechin helped limit several molecular signs of spinal cord damage progression in this experimental model.
What this means in real life: Spinal cord injury involves more than the initial trauma. Secondary damage can affect blood vessels, glial activity, myelin, neurons, and axonal structure over time. In this animal model, (+)-epicatechin appeared to preserve several of these biological markers while supporting better movement recovery. This does not mean (+)-epicatechin is a proven treatment for spinal cord injury in humans, but it adds to the scientific interest around epicatechin-related compounds, neural protection, vascular stability, and recovery biology.
Clinical Relevance: Rat study, moderate traumatic spinal cord injury model, locomotor recovery, neural damage markers, and protein analysis; not human clinical trial evidence.
Related Content:
- For the cellular energy foundation behind recovery biology → What Does “Mitochondrial Dysfunction” Actually Feel Like?
- For practical ways to support mitochondrial capacity over time → How Long Does It Take to Improve My Mitochondria? A Realistic Timeline for Beginners
- For a broader look at cellular energy and fatigue → Why Am I Always Tired?
(+)-Epicatechin and Spinal Cord Injury Recovery in Rats
Epicatechin, Muscle Growth Markers, and Age-Related Muscle Function
Study Title: Effects of (-)-epicatechin on molecular modulators of skeletal muscle growth and differentiation
Citation: Gutierrez-Salmean et al., 2014 · The Journal of Nutritional Biochemistry
What the Study Found: This study examined age-related changes in skeletal muscle growth and differentiation markers in mice and humans, then tested short-term (-)-epicatechin exposure. In aged mice, myostatin and senescence-associated β-galactosidase were higher, while follistatin and Myf5 were lower. (-)-Epicatechin reduced myostatin and β-galactosidase and increased markers associated with muscle growth. In the human proof-of-concept portion, older muscle showed a similar age-related pattern, and seven days of (-)-epicatechin increased hand grip strength and the plasma follistatin-to-myostatin ratio.
What this means in real life: This study supports the idea that aging muscle is affected not only by loss of mass, but also by changes in the signaling environment around muscle growth, differentiation, and cellular senescence. In this early research, (-)-epicatechin was associated with more favorable muscle-related markers and a short-term increase in grip strength. This does not mean (-)-epicatechin treats sarcopenia or reverses muscle aging in humans. It does suggest that muscle resilience and healthy aging may be linked to molecular signals that can be studied and potentially supported.
Clinical Relevance: Mouse and small human proof-of-concept study, aging skeletal muscle, muscle growth and differentiation markers, and short-term (-)-epicatechin exposure.
Related Content:
- Want to understand how mitochondrial health connects to muscle loss? → Rare Neuromuscular Diseases and Muscle Atrophy: A Mitochondrial Lens
- Curious how muscle recovery unfolds over time? → Muscle Recovery Has Phases: Immediate, 24–48 Hours, and Long-Term Adaptation
- Looking for the broader epicatechin and mitochondrial support context? → Mitozz, (-)-Epicatechin and “Mitochondrial Support”